21st Century Cures Act Passes in the House
On Friday, July 10th, the U.S. House voted overwhelmingly to streamline the approval process of prescription drugs and medical devices by the FDA.
News
Post-Translationally Modified Proteins as Potential New Early Arthritis Activity Markers
Defects in protein citrullination and its consequences in patients with RA have been studied widely in the recent decade. It appears that autoantibodies, including those against citrullinated proteins, are of diagnostic and prognostic relevance.
The High Cost and Burden of Sepsis
One million people are hospitalized each year with sepsis. This is more than the number of hospitalizations for heart attack and stroke combined. Sepsis can be a particular risk for older people.
Factors Affecting Opiate Abuse Identified
Researchers have determined that adults aged 50 and above were more likely to acquire pain relievers through more than one doctor, whereas younger individuals were more likely to acquire them from friends, relatives or drug dealers.
FDA Strengthens MI and CVA Risks Associated with NSAIDs
FDA announced yesterday they would strengthen warnings stating that non-aspirin nonsteroidal anti-inflammatory drugs increase the chance of a heart attack or stroke. This applies to both prescription and OTC NSAIDs.
The Differential Diagnosis of Heel Pain
A slim, yoga bending, middle aged school teacher seeks a rheumatology consultation to determine the cause and cure for her left lateral heel pain for the past 6 months. No trauma, no crazy footwear and no systemic symptoms, uveitis, or peripheral/axial arthritis.
Health Canada Issues Acetaminophen Advisory
Yesterday Health Canada announced it “is taking additional steps to minimize the risk of liver damage and improve acetaminophen safety,” citing the findings of a government review that underscored the possibility of accidental overdose.
Does ACPA Increase the Risk of Interstitial Lung Disease?
The anti-citrullinated peptide (anti-CCP or ACPA) antibody assay has a specificity of greater than 90% for rheumatoid arthritis and is associated with worse articular outcomes.
Guselkumab Tops Adalimumab in Psoriasis Trial
NEJM reports a 52 week, phase II trial in 293 adult patients with moderate-to-severe psoriasis (>10 BSA) who were randomized to receive either placebo, adalimumab or guselkumab - a novel IL-23 inhibitor.
Safety of Colchicine in End Stage Renal Disease
Colchicine toxicity has been linked to renal function and it has generally been advised to adjust colchicine dosing in patients with renal insufficiency.
Brodalumab Backlash
On May 26, RheumNow.com reported that Amgen and Astra-Zenica suspended drug development for the IL-17 inhibitor brodalumab.
Neurologic Events with TNF Inhibitor Therapy
Demyelinating disorders are an uncommon complication of TNF inhibition and have been described with all TNF inhibitors but also with other biologics.
